Login to Your Account

New CEO in place with funding

Astrazeneca plc spinout Corvidia Therapeutics Inc.'s $60 million in series B money should let the company "expand into earlier stages of chronic kidney disease [CKD] and apply our scientific approach further into areas of heart failure," CEO Marc de Garidel told BioWorld.

more »

Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.



Partners in Focus